• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TELA Bio Appoints Renowned Surgeon as Vice President of Clinical Development

    1/5/21 7:00:00 AM ET
    $TELA
    Medical/Dental Instruments
    Health Care
    Get the next $TELA alert in real time by email

    Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options

    MALVERN, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), an innovative MedTech company focused on advancing the field of soft-tissue reconstruction, announced today that it has welcomed Bruce Freedman, M.D., FACS as Vice President of Clinical Development. After 32 years as a private practice general surgeon specializing in hernia repair and abdominal wall reconstruction, Dr. Freedman has joined TELA Bio to advocate for a more natural hernia repair mesh option as an alternative to permanent and resorbable synthetic mesh.

    “As a surgeon who has performed thousands of hernia repairs with plastic mesh over the past three decades, I fully understand the clinical limitations of using synthetic mesh to repair human tissue,” said Dr. Freedman. “Unfortunately, plastic mesh has the potential to create a foreign body response and inflammation in some patients, the effects of which can cause complications immediately after surgery or even many years down the road. OviTex® is a very different material and was designed specifically to reduce this foreign-body response. As I incorporated it in my practice, I saw first-hand how the careful work that went into the design positively impacted my patients.” He added, “TELA Bio is providing much needed innovation in the hernia repair specialty, and I believe this product has remarkable potential to help surgeons break decades-long dependence on plastic mesh, while advancing treatment and better serving the patient.”

    In his role, Dr. Freedman will be using his extensive experience as a healthcare provider to share the clinical and financial benefits of the OviTex Reinforced Tissue Matrix portfolio with surgeons and hospital administration. “TELA Bio has spent the past several years working closely with surgeons in capturing and documenting clinical and financial evidence. They’ve got a powerful message, one I’m enthusiastic to help spread,” Dr. Freedman added.

    “We are thrilled to welcome Dr. Freedman to our team. Improving patient access to our innovative technology requires education throughout the healthcare delivery system, which includes surgeons, clinical resources, supply chain, hospital administrators, and patients,” said Antony Koblish, Co-founder, President, and Chief Executive Officer, TELA Bio. “Dr. Freedman adds a credible, experienced voice that will help distinguish us from the many larger, legacy companies. Like us, he shares a passion for safer hernia repair and his decision to join our mission further reinforces the critical need to offer patients a more natural hernia repair.”

    To find practicing surgeons throughout the country who believe in providing patients with a more natural hernia repair option, click here. 

    About TELA Bio, Inc.
    TELA Bio, Inc. is a commercial stage medical technology company focused on designing, developing, and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. TELA Bio's products are designed to improve on shortcomings of existing biologics and minimize long-term exposure to permanent synthetic material. TELA Bio's portfolio is supported by quality, data-driven science, and extensive pre-clinical research that has consistently demonstrated advantages over other commercially available products.

    About OviTex
    OviTex Reinforced Tissue Matrix is intended for use as a surgical mesh to reinforce and/or repair soft tissue where weakness exists. Indications for use include the repair of hernias and/or abdominal wall defects that require the use of reinforcing or bridging material to obtain the desired surgical outcome. Do not use OviTex in patients known to be sensitive to materials of ovine (sheep) origin. For prescription use only. For additional important safety information, please see the OviTex Reinforced Tissue Matrix Instructions for Use.

    The statements made or results achieved by TELA Bio customers described herein were achieved in their specific setting. Due to variations in clinical experience and technique, there is no guarantee that these results are typical. A surgeon must use his or her own clinical judgment when deciding which products are appropriate for treatment of a particular patient. Always refer to the package insert, product label, and/or instructions for use before using any TELA Bio product. Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets.

     
    Get the next $TELA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TELA

    DatePrice TargetRatingAnalyst
    3/21/2025$5.00 → $2.00Overweight → Neutral
    Piper Sandler
    5/31/2022$17.00Buy
    Lake Street
    More analyst ratings

    $TELA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her ac

      5/9/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TELA Bio downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded TELA Bio from Overweight to Neutral and set a new price target of $2.00 from $5.00 previously

      3/21/25 8:05:03 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on TELA Bio with a new price target

      Lake Street initiated coverage of TELA Bio with a rating of Buy and set a new price target of $17.00

      5/31/22 9:13:36 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • COO and CFO Cuca Roberto bought $144,999 worth of shares (64,444 units at $2.25), increasing direct ownership by 71% to 155,388 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:26:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Talmo Paul bought $50,000 worth of shares (22,222 units at $2.25), increasing direct ownership by 32% to 91,082 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:59 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony bought $199,998 worth of shares (88,888 units at $2.25), increasing direct ownership by 24% to 458,897 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      10/24/24 4:25:31 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    SEC Filings

    See more
    • SEC Form 10-Q filed by TELA Bio Inc.

      10-Q - TELA Bio, Inc. (0001561921) (Filer)

      5/8/25 4:30:27 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - TELA Bio, Inc. (0001561921) (Filer)

      5/8/25 4:15:49 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TELA Bio Inc.

      SCHEDULE 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      5/8/25 7:57:51 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Talmo Paul covered exercise/tax liability with 190 shares, decreasing direct ownership by 0.15% to 123,882 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:49:36 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Accounting Officer Smeykal Megan covered exercise/tax liability with 96 shares, decreasing direct ownership by 0.26% to 36,831 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:46:56 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Koblish Antony covered exercise/tax liability with 384 shares, decreasing direct ownership by 0.07% to 590,110 units (SEC Form 4)

      4 - TELA Bio, Inc. (0001561921) (Issuer)

      4/2/25 4:45:22 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      11/14/24 1:06:57 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by TELA Bio Inc.

      SC 13G - TELA Bio, Inc. (0001561921) (Subject)

      10/29/24 5:12:40 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TELA Bio Inc.

      SC 13G/A - TELA Bio, Inc. (0001561921) (Subject)

      10/28/24 4:06:51 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Leadership Updates

    Live Leadership Updates

    See more
    • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

      MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

      6/4/24 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

      MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

      5/20/24 4:03:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

      MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where

      4/8/24 7:00:00 AM ET
      $TELA
      Medical/Dental Instruments
      Health Care

    $TELA
    Financials

    Live finance-specific insights

    See more
    • TELA Bio Reports First Quarter 2025 Financial Results

      MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;Commenced full U.S. comme

      5/8/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio to Announce First Quarter 2025 Financial Results

      MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the

      4/17/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care
    • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

      3/20/25 4:05:00 PM ET
      $TELA
      Medical/Dental Instruments
      Health Care